NAGE · Nasdaq · ·
下次财报:2026年11月3日
US$2.97-1.2%9月29日 收盘
Niagen Bioscience, Inc. 预定于 2026年11月3日发布下一份财报。日期来自 Nasdaq 财报日历,公司有时会调整。
截至 2026年6月30日 的季度,与去年同季度相比。
| 指标 | 截至该日的 3 个月2026年6月30日 | 截至该日的 3 个月2025年6月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$29.8M | US$31.1M | -4.28% |
| 利润 | US$963K | US$3.6M | -73.32% |
| 每股收益 | US$0.01 | US$0.04 | -75.00% |
| 自由现金流 | -US$3.9M | -US$7.9M | +50.92% |
这些是单季度数字,不是滚动一年——本站其他地方的数字覆盖十二个月,会大得多。季节性业务在两者之间摆动很大:ServiceNow 在十二月季度赚 20 亿美元自由现金流,在六月季度只有 5 亿。
对比对象是去年同一季度,而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据,那是我们没有的授权数据——而搞错它比不提更糟。
暂无 Niagen Bioscience, Inc. 的业绩电话会文字记录。
“During the quarter, Tru Niagen continued to demonstrate its category leadership, and at the same time, we laid the foundation strategically for what we expect will unlock tremendous value for years to come. The launch of our telehealth business and pharmaceutical program are long-term growth drivers that have evolved Niagen from a nutritional supplement business to a multi-asset anti-aging company,”
逐字引自公告,且只在文件将其归于具名人士时才展示。
公告在收盘后或开盘前发布,因此这里的变动是随后的那个交易日。
Bioscience, Inc.: Niagen Bioscience is a global bioscience company focused on healthy aging. The Company is a leader in research on NAD+ (nicotinamide adenine dinucleotide), an essential coenzyme that supports cellular metabolism and declines with age. Niagen Bioscience is the innovator of nicotinamide riboside chloride (“NRC” or “NRCL,” commonly referred to as “NR”), a patented NAD+ precursor commercialized as Niagen®, available in both food-grade and pharmaceutical-grade forms. Nicotinamide riboside chloride and other NAD+ precursors are protected by Niagen Bioscience’s patent portfolio. The Company markets its consumer supplement Tru Niagen® and develops and supplies Niagen® as a proprietary ingredient to partners across the health and wellness and pharmaceutical sectors. Niagen Bioscience is also advancing research and development of NAD+ precursor-based technologies for potential therapeutic applications. Follow us on X (formerly Twitter) @NiagenBio and Instagram @TruNiagen and @NiagenPlus and subscribe to our latest news via our website accessible at www.NiagenBioscience.com to which Niagen Bioscience regularly posts copies of its press releases as well as additional updates and financial information about the Company.
公司自己的描述,取自公告末尾。
引述和公司简介来自 Niagen Bioscience, Inc. 于 2026年8月4日 提交的第 2.02 项 8-K 文件;表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。